Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128]
Titel:
Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128]
Auteur:
Gogas, Helen Dummer, Reinhard Ascierto, Paolo A. Arance, Ana Mandalà, Mario Liszkay, Gabriella Garbe, Claus Schadendorf, Dirk Krajsová, Ivana Gutzmer, Ralf Chiarion Sileni, Vanna Dutriaux, Caroline Yamazaki, Naoya Loquai, Carmen Queirolo, Paola de Willem, Groot J. Sellier, Abir T. Suissa, Jeanne Murris, Juliette Gollerkeri, Ashwin Robert, Caroline Flaherty, Keith T.